GO:0010868 negative regulation of triglyceride biosynthetic process: Lipid Droplet Turnover, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010868 describes any process that decreases the rate, frequency, or extent of triglyceride biosynthesis, the formation of a triester of glycerol.
• Negative regulation of triglyceride biosynthesis is essential for preventing excessive lipid storage in adipose tissue, liver, and other metabolic organs.
• Key negative regulators include lipolytic enzymes and lipid droplet-associated proteins such as CIDEC, which restrict liver regeneration by disturbing lipid droplet triglyceride turnover.
• Dysregulation of this process contributes to steatosis, insulin resistance, ectopic fat deposition, and cardiovascular risk.
• Gut microbiota and bile acid metabolism can indirectly suppress hepatic triglyceride accumulation and ketogenesis.
• CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect causal roles of candidate genes in this regulatory process.
Description
Triglycerides are the primary form of stored energy in mammals, and their biosynthesis must be tightly controlled to match energy demand and prevent lipotoxicity. The Gene Ontology term GO:0010868, negative regulation of triglyceride biosynthetic process, captures all molecular and cellular events that decrease the rate, frequency, or extent of triglyceride formation. This process is distinct from lipolysis, although the two are functionally coupled: increased lipolysis can reduce substrate availability for triglyceride synthesis and thus indirectly suppress triglyceride biosynthesis. Understanding this regulatory node is critical because excessive triglyceride accumulation underlies fatty liver disease, obesity, insulin resistance, and cardiometabolic disorders. At the cellular level, triglyceride biosynthesis occurs mainly in the endoplasmic reticulum and lipid droplets, and its negative regulation can be achieved by limiting substrate supply, inhibiting biosynthetic enzymes, or promoting triglyceride turnover within lipid droplets. For example, CIDEC (cell death-inducing DFFA-like effector C) restricts liver regeneration by disturbing lipid droplet triglyceride turnover, illustrating how a single protein can negatively regulate triglyceride accumulation and impact tissue repair. Similarly, prostaglandin E2 signaling through the EP4 receptor promotes lipolysis and fibrosis in adipose tissue, leading to ectopic fat deposition and insulin resistance, which indirectly reflects reduced triglyceride storage. Researchers study GO:0010868 to identify therapeutic targets for metabolic diseases and to understand how tissues balance energy storage versus utilization. The process is also influenced by systemic factors such as gut microbiota and bile acid metabolism, which can suppress hepatic triglyceride accumulation and ketogenesis. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of the genes, mechanisms, disease links, and experimental models relevant to negative regulation of triglyceride biosynthetic process.
negative regulation of triglyceride biosynthetic process At A Glance
| GO ID | GO:0010868 |
|---|---|
| GO term | negative regulation of triglyceride biosynthetic process |
| Ontology | biological_process |
| Synonym | negative regulation of triacylglycerol biosynthetic process |
| Definition | Any process that decreases the rate, frequency, or extent of triglyceride biosynthesis, the formation of a triester of glycerol. |
| Major function | Suppression of triglyceride synthesis and storage to maintain lipid homeostasis and prevent lipotoxicity. |
| Related processes | Lipolysis, lipid droplet turnover, fatty acid oxidation, ketogenesis. |
| Key regulators | Lipases, lipid droplet proteins (e.g., CIDEC), prostaglandin signaling, gut microbiota-derived metabolites. |
| Disease relevance | Hepatic steatosis, insulin resistance, ectopic fat deposition, cardiovascular risk. |
What Is GO:0010868?
GO:0010868, negative regulation of triglyceride biosynthetic process, is defined as any process that decreases the rate, frequency, or extent of triglyceride biosynthesis. Triglyceride biosynthesis is the collection of chemical reactions and pathways resulting in the formation of triglyceride, any triester of glycerol. This term encompasses molecular events that inhibit the enzymatic steps of triglyceride synthesis, reduce the availability of substrates such as fatty acyl-CoA and glycerol-3-phosphate, or enhance the turnover of triglyceride within lipid droplets, thereby lowering net triglyceride accumulation. It is a biological process term and is synonymous with negative regulation of triacylglycerol biosynthetic process.
Why Is negative regulation of triglyceride biosynthetic process Important in Cell Biology?
Negative regulation of triglyceride biosynthetic process is a central safeguard against excessive lipid accumulation, which can impair organ function and contribute to metabolic disease. In the liver, uncontrolled triglyceride synthesis leads to steatosis and non-alcoholic fatty liver disease, while in adipose tissue it promotes hypertrophy and inflammation. Understanding how this process is negatively regulated provides mechanistic insight into insulin resistance, dyslipidemia, and cardiovascular risk, and identifies candidate targets for therapeutic intervention.
• Prevents hepatic steatosis by limiting triglyceride accumulation in hepatocytes.
• Maintains adipose tissue function and prevents ectopic fat deposition.
• Couples lipid storage with energy demand through lipolysis and fatty acid oxidation.
• Modulates insulin sensitivity and systemic glucose homeostasis.
• Influences liver regeneration through lipid droplet turnover.
• Links gut microbiota and bile acid metabolism to hepatic lipid control.
• Provides targets for treating dyslipidemia and cardiometabolic disease.
• Helps explain inter-individual variation in response to high-fat diets.
• Guides development of CRISPR models for metabolic gene function.
• Supports biomarker discovery such as triglyceride-glucose index for stroke risk.
What Happens During negative regulation of triglyceride biosynthetic process?
Reduced substrate supply for triglyceride synthesis
In simple terms: When cells break down fat faster than they build it, there are fewer building blocks available to make triglycerides.
Triglyceride biosynthesis requires fatty acyl-CoA and glycerol-3-phosphate. Negative regulation can occur when lipolysis is enhanced, releasing free fatty acids and glycerol that are either oxidized or exported rather than re-esterified. Prostaglandin E2 signaling through EP4 promotes lipolysis in adipose tissue, reducing the availability of fatty acids for triglyceride synthesis and leading to ectopic fat deposition and insulin resistance. Thus, increased lipolytic flux is a major mechanism that decreases the rate of triglyceride biosynthesis.
Inhibition of biosynthetic enzymes
In simple terms: The enzymes that build triglycerides can be slowed down or turned off, directly lowering triglyceride production.
The terminal steps of triglyceride synthesis are catalyzed by diacylglycerol acyltransferases (DGATs). Negative regulation of this process can involve decreased expression or activity of DGAT enzymes, although direct evidence in the provided literature is limited. More broadly, high-fat diet-induced liver steatosis involves coordinated transcriptional and translational changes in lipid metabolic enzymes, and negative regulation may occur at these levels. The QuickGO definition encompasses any process that decreases the rate of triglyceride biosynthesis, including post-transcriptional and post-translational inhibition of biosynthetic enzymes.
Lipid droplet turnover and CIDEC function
In simple terms: Fat droplets inside cells can be broken down or remodeled, which reduces the amount of stored triglyceride.
Lipid droplets are the primary storage sites for triglycerides. CIDEC is a lipid droplet-associated protein that restricts liver regeneration by disturbing lipid droplet triglyceride turnover. This indicates that proteins controlling lipid droplet dynamics can negatively regulate triglyceride accumulation by promoting turnover or preventing excessive lipid storage. The interplay between lipid droplet stability and triglyceride biosynthesis is therefore a key node in this GO term.
Systemic and microbial influences
In simple terms: Gut bacteria and bile acids can send signals to the liver that reduce fat production.
Gut microbiota regulates hepatic ketogenesis and lipid accumulation in ketogenic diet-induced hyperketonemia by disrupting bile acid metabolism. This systemic regulation can suppress hepatic triglyceride accumulation, illustrating that negative regulation of triglyceride biosynthetic process is not solely cell-autonomous but can be influenced by microbial and bile acid signals. Such findings expand the physiological scope of GO:0010868 to include host-microbe interactions.
Translational and transcriptional control
In simple terms: Cells can adjust how much protein is made from lipid-related genes, which changes how fast triglycerides are built.
Comprehensive translatome analysis in high-fat diet-induced liver steatosis reveals a relationship between translational and transcriptional control of lipid metabolic genes. Negative regulation of triglyceride biosynthesis can be achieved by reducing the translation or transcription of enzymes involved in the pathway, thereby lowering the capacity for triglyceride synthesis. This layer of regulation is important for understanding adaptive responses to nutrient excess.
Key Genes Involved in GO:0010868 negative regulation of triglyceride biosynthetic process
The following genes and proteins have been implicated in negative regulation of triglyceride biosynthetic process or closely related lipid metabolic pathways based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CIDEC | Lipid droplet-associated protein that disturbs triglyceride turnover and restricts liver regeneration | Target for studying lipid droplet dynamics and liver regeneration |
| PNPLA2 (ATGL) | Catalyzes the first step of lipolysis, reducing substrate for triglyceride synthesis | Key node in negative regulation of triglyceride storage |
| LIPE (HSL) | Hormone-sensitive lipase that hydrolyzes stored triglycerides | Regulates lipolysis and fatty acid release |
| MGLL | Monoglyceride lipase completing lipolysis | Contributes to reduced re-esterification |
| PTGER4 (EP4) | Prostaglandin E2 receptor that promotes lipolysis and fibrosis | Links inflammation to ectopic fat deposition |
| DGAT1 | Diacylglycerol acyltransferase catalyzing terminal triglyceride synthesis | Potential target for inhibiting triglyceride biosynthesis |
| DGAT2 | Diacylglycerol acyltransferase involved in triglyceride synthesis | Isoform-specific regulation of lipid storage |
| GPAM | Glycerol-3-phosphate acyltransferase, first committed step of triglyceride synthesis | Upstream control point for negative regulation |
| AGPAT | Acylglycerol-3-phosphate acyltransferase in triglyceride synthesis | Enzyme node for substrate channeling |
| PAP | Phosphatidate phosphatase producing diacylglycerol | Regulatory step in triglyceride synthesis |
| FABP4 | Fatty acid binding protein affecting lipid trafficking | Modulates substrate availability |
| CD36 | Fatty acid translocase influencing lipid uptake | Affects substrate supply for triglyceride synthesis |
| PPARA | Nuclear receptor promoting fatty acid oxidation | Shifts balance away from triglyceride storage |
| PPARG | Nuclear receptor promoting adipogenesis and lipid storage | Counter-regulatory role in triglyceride accumulation |
| INSIG1 | Regulates SREBP processing and lipogenic gene expression | Transcription-level control of lipogenesis |
| SREBF1 | Master transcription factor for lipogenic genes | Target for negative regulation of triglyceride synthesis |
| CIDEA | Lipid droplet protein related to CIDEC | Potential modifier of lipid droplet turnover |
| CIDEB | Lipid droplet protein involved in lipid metabolism | Candidate for lipid droplet regulation |
How Is negative regulation of triglyceride biosynthetic process Regulated?
Negative regulation of triglyceride biosynthetic process is controlled at multiple levels. Hormonal signals such as prostaglandin E2 via EP4 promote lipolysis and reduce triglyceride storage. Nutrient status and gut microbiota-derived bile acids can suppress hepatic triglyceride accumulation and ketogenesis. Transcriptional and translational programs adjust the expression of lipogenic enzymes in response to high-fat diets. Additionally, lipid droplet-associated proteins like CIDEC modulate triglyceride turnover and liver regeneration. Together, these layers ensure that triglyceride biosynthesis is decreased when energy demand is high or when lipid storage capacity is exceeded.
negative regulation of triglyceride biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CIDEC | Liver regeneration and lipid droplet turnover | Knockout and overexpression in hepatocytes |
| PTGER4 | Ectopic fat deposition and insulin resistance | Adipose-specific knockout or agonist treatment |
| DGAT1 | Hepatic steatosis and dyslipidemia | Liver-specific knockout and point mutation |
| DGAT2 | Triglyceride synthesis and lipid storage | Knockout and knock-in models |
| SREBF1 | Lipogenesis and fatty liver | Overexpression and knockout in liver |
Hepatic steatosis and non-alcoholic fatty liver disease
Impaired negative regulation of triglyceride biosynthesis leads to excessive hepatic triglyceride accumulation, a hallmark of steatosis and non-alcoholic fatty liver disease. High-fat diet-induced liver steatosis involves coordinated changes in translation and transcription of lipid metabolic genes, and failure to suppress triglyceride synthesis exacerbates lipid deposition. CIDEC disturbs lipid droplet triglyceride turnover and restricts liver regeneration, linking defective negative regulation to impaired liver repair.
Insulin resistance and ectopic fat deposition
Prostaglandin E2-EP4 axis promotes lipolysis and fibrosis in adipose tissue, leading to ectopic fat deposition and insulin resistance. When negative regulation of triglyceride biosynthesis is dysregulated, lipids accumulate in non-adipose tissues such as liver and muscle, contributing to systemic insulin resistance. This connection highlights the importance of this GO term in metabolic syndrome.
Cardiometabolic risk and stroke
The triglyceride-glucose index, a surrogate marker of triglyceride metabolism, predicts incident stroke across glycaemic-regulation subgroups. This underscores the clinical relevance of triglyceride regulation, including negative regulation of triglyceride biosynthetic process, in cardiovascular risk assessment. Dyslipidemia and altered triglyceride handling are established contributors to atherosclerotic risk.
Gut microbiota and ketogenic diet-induced hyperketonemia
Gut microbiota regulates hepatic ketogenesis and lipid accumulation in ketogenic diet-induced hyperketonemia by disrupting bile acid metabolism. This indicates that microbial signals can suppress hepatic triglyceride accumulation, and dysbiosis may impair negative regulation of triglyceride biosynthesis. Understanding these interactions may inform probiotic or dietary interventions.
From negative regulation of triglyceride biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase triglyceride biosynthesis? | CRISPR knockout in hepatocytes or adipocytes |
| Does a specific mutation alter enzyme activity in triglyceride synthesis? | Point mutation knock-in |
| Does overexpression of a negative regulator reduce lipid accumulation? | Overexpression cell model |
| How does a tagged protein localize to lipid droplets? | Tagged knock-in |
| Which genes regulate triglyceride biosynthesis in a genome-wide manner? | CRISPR library screening |
| What are the transcriptomic and translational changes under high-fat diet? | RNA-seq and Ribo-seq in knockout models |
How to Study the negative regulation of triglyceride biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript abundance of lipid metabolic genes | Identify transcriptional changes in negative regulation |
| Ribo-seq | Translational efficiency of mRNAs | Detect translational control of triglyceride enzymes |
| Lipidomics | Triglyceride species and total lipid content | Quantify net effect on triglyceride biosynthesis |
| BODIPY staining | Lipid droplet number and size | Visualize lipid droplet turnover |
| CRISPR knockout | Loss-of-function effects on triglyceride levels | Validate candidate negative regulators |
| Overexpression | Gain-of-function effects on lipid accumulation | Test sufficiency of a negative regulator |
| Western blot | Protein expression of lipogenic enzymes | Confirm changes in enzyme abundance |
| qPCR | mRNA levels of target genes | Rapid assessment of transcriptional regulation |
Transcriptomic and translatomic profiling
RNA-seq and Ribo-seq can reveal transcriptional and translational changes in lipid metabolic genes under conditions that negatively regulate triglyceride biosynthesis, such as high-fat diet or genetic perturbation. These methods help identify upstream regulators and downstream effectors of GO:0010868.
Lipidomics and triglyceride quantification
Mass spectrometry-based lipidomics and enzymatic triglyceride assays quantify the net effect of negative regulation on triglyceride levels. Such measurements are essential to validate whether a candidate gene truly decreases triglyceride biosynthesis.
Imaging of lipid droplets
Fluorescence microscopy with lipid droplet dyes (e.g., BODIPY) and tagged lipid droplet proteins can visualize changes in droplet size, number, and turnover. This is particularly useful for studying CIDEC and related proteins.
CRISPR-based functional screens
Genome-wide CRISPR knockout or activation screens can identify negative regulators of triglyceride biosynthesis by selecting cells with altered lipid content. Hits can be validated individually using targeted knockout or overexpression.
How CRISPR Can Be Used to Study GO:0010868 negative regulation of triglyceride biosynthetic process
Knockout
CRISPR knockout of candidate genes such as CIDEC or DGAT1 can test whether loss of function increases triglyceride biosynthesis, thereby confirming their role as negative regulators. Knockout models in hepatocytes or adipocytes are widely used to study lipid accumulation.
Point Mutation
Point mutation knock-in can dissect catalytic residues or regulatory phosphorylation sites in enzymes like DGAT1 or lipases, revealing how specific amino acid changes alter negative regulation of triglyceride biosynthesis.
Knock-in
Knock-in of tagged versions of lipid droplet proteins such as CIDEC allows real-time tracking of protein localization and turnover, providing mechanistic insight into how these proteins disturb triglyceride storage.
Overexpression
Overexpression of negative regulators like PTGER4 or CIDEC can reduce triglyceride accumulation and reverse steatosis in cell models, demonstrating sufficiency and therapeutic potential.
How EDITGENE Supports negative regulation of triglyceride biosynthetic process Research
Researchers studying negative regulation of triglyceride biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in suppressing triglyceride synthesis or whether its effect is secondary to broader metabolic changes. Rigorous causal inference requires precise genetic models that can isolate loss-of-function, gain-of-function, and specific mutation effects in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of triglyceride biosynthetic process research.
Frequently Asked Questions About negative regulation of triglyceride biosynthetic process
What is GO:0010868 negative regulation of triglyceride biosynthetic process?
It is a Gene Ontology biological process term describing any process that decreases the rate, frequency, or extent of triglyceride biosynthesis, the formation of a triester of glycerol.
What genes are involved in negative regulation of triglyceride biosynthetic process?
Key genes include CIDEC, PNPLA2 (ATGL), LIPE (HSL), MGLL, PTGER4, DGAT1, DGAT2, and transcription factors such as SREBF1 and INSIG1.
How does CIDEC regulate triglyceride biosynthesis?
CIDEC is a lipid droplet-associated protein that disturbs lipid droplet triglyceride turnover and restricts liver regeneration, thereby negatively regulating triglyceride accumulation.
What is the role of lipolysis in negative regulation of triglyceride biosynthesis?
Lipolysis breaks down stored triglycerides and reduces fatty acid availability for re-esterification, indirectly decreasing the rate of triglyceride biosynthesis.
How does gut microbiota affect hepatic triglyceride accumulation?
Gut microbiota regulates hepatic ketogenesis and lipid accumulation by disrupting bile acid metabolism, which can suppress triglyceride accumulation.
What diseases are linked to dysregulation of triglyceride biosynthesis?
Hepatic steatosis, insulin resistance, ectopic fat deposition, and increased cardiovascular risk including stroke are linked to dysregulated triglyceride metabolism.
What experimental models are used to study negative regulation of triglyceride biosynthesis?
CRISPR knockout, point mutation knock-in, tagged knock-in, overexpression cell models, and CRISPR library screens are commonly used.
How is triglyceride biosynthesis measured in the lab?
Lipidomics, enzymatic triglyceride assays, BODIPY staining of lipid droplets, and RNA-seq or Ribo-seq of lipid metabolic genes are typical methods.
Can CRISPR screens identify new negative regulators of triglyceride biosynthesis?
Yes, genome-wide CRISPR knockout or activation screens can uncover novel regulators by selecting cells with altered lipid content.
Why is negative regulation of triglyceride biosynthesis important for metabolic health?
It prevents excessive lipid storage, maintains insulin sensitivity, and reduces risk of fatty liver disease and cardiometabolic disorders.
Conclusion
GO:0010868 negative regulation of triglyceride biosynthetic process is a critical biological process that safeguards against excessive lipid accumulation and metabolic dysfunction. Its mechanisms span lipolysis, lipid droplet turnover, transcriptional and translational control, and systemic signals from gut microbiota and bile acids. Dysregulation of this process contributes to steatosis, insulin resistance, ectopic fat deposition, and cardiovascular risk. CRISPR-based knockout, point mutation, knock-in, and overexpression models, combined with CRISPR library screening and bioinformatics, provide powerful tools to dissect causal genes and identify therapeutic targets.
References
- 1. Cho CH et al.. 2023. Adipose tissue lipid metabolism: lipolysis.. Curr Opin Genet Dev 83:102114 PMID: 37738733
- 3. Luo Z et al.. 2025. Gut microbiota regulates hepatic ketogenesis and lipid accumulation in ketogenic diet-induced hyperketonemia by disrupting bile acid metabolism.. Gut Microbes 17(1):2496437 PMID: 40268803
- 5. Zou X et al.. 2025. Additive value of combining triglyceride-glucose index and estimated glucose disposal rate for incident stroke prediction across glycaemic-regulation subgroups: a prospective cohort of 5,789 Chinese adults.. Cardiovasc Diabetol 25(1):21 PMID: 41398673
- 6. Luo Z et al.. 2021. Comprehensive analysis of the translatome reveals the relationship between the translational and transcriptional control in high fat diet-induced liver steatosis.. RNA Biol 18(6):863-874 PMID: 32967529
- 7. Inazumi T et al.. 2020. Prostaglandin E(2)-EP4 Axis Promotes Lipolysis and Fibrosis in Adipose Tissue Leading to Ectopic Fat Deposition and Insulin Resistance.. Cell Rep 33(2):108265 PMID: 33053354
- 8. Ouyang F et al.. 2026. CIDEC Restricts Liver Regeneration by Disturbing Lipid Droplet Triglyceride Turnover.. Adv Sci (Weinh) 13(3):e07048 PMID: 41255220
